Eastern Hepatobiliary Surgery Hospital
🇨🇳China
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT06530823
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06013943
- Locations
- 🇨🇳
Easter hepatobiliary surgery hospital, Shanghai, Shanghai, China
Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05925413
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
A Prospective Cohort Study on the Prediction of PHLF by Comparing the Prediction Model Based on VEGFA and PEDF With Indocyanine Green Clearance Test
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05779098
A Study of Danning Tablet in Patients With Polypoid Lesions of Gallbladder
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 336
- Registration Number
- NCT05668871
- Locations
- 🇨🇳
The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
🇨🇳Eastern Hepatobiliary Surgery Hospital, Naval Medical University,, Shanghai, Shanghai, China
🇨🇳Loudi Central Hospital, Loudi, Hunan, China
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 492
- Registration Number
- NCT05667350
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 286
- Registration Number
- NCT05540925
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Naval Medical University,, Shanghai, Shanghai, China
Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT04891874
- Locations
- 🇨🇳
Second Military Medical University, Shanghai, Shanghai, China
Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 320
- Registration Number
- NCT04523467
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04523402
© Copyright 2024. All Rights Reserved by MedPath